In conclusion, our study results elucidate that miR-30a-3p intervention affects BC in two manners: [1] by directly targeting ATG5, ATG12, and Beclin 1 to impair cisplatin-induced protective autophagy and leading to slow tumor growth and [2] by reducing the expression of MMP2 and MMP9 in tumors, thus inhibiting cell invasiveness in vitro and muscle invasion in vivo (Fig. 9). The gene discussed is BECN1; the disease is breast cancer.